Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Epirubicin hydrochloride
Drug ID BADD_D00785
Description An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Indications and Usage For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Marketing Status approved
ATC Code L01DB03
DrugBank ID DB00445
KEGG ID D02214
MeSH ID D015251
PubChem ID 65348
TTD Drug ID D0C9XJ
NDC Product Code 0143-9202; 0009-5091; 0009-5093; 77391-002; 0143-9203
UNII 22966TX7J5
Synonyms Epirubicin | 4'-Epidoxorubicin | 4' Epidoxorubicin | 4'-Epi-Doxorubicin | 4' Epi Doxorubicin | 4'-Epi-Adriamycin | 4' Epi Adriamycin | 4'-Epiadriamycin | 4' Epiadriamycin | 4'-Epi-DXR | 4' Epi DXR | EPI-cell | EPI cell | EPIcell | Epilem | Farmorubicina | IMI-28 | IMI 28 | IMI28 | NSC-256942 | NSC 256942 | NSC256942 | Ellence | Pharmorubicin | Farmorubicine | Farmorubicin | Epirubicin Hydrochloride | Hydrochloride, Epirubicin
Chemical Information
Molecular Formula C27H29NO11.ClH
CAS Registry Number 25316-40-9
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O .Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.01.045--
Stomatitis07.05.06.005--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytosis01.08.02.001--Not Available
Thrombophlebitis24.01.02.001--Not Available
Toxic epidermal necrolysis10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.006--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Venous thrombosis24.01.01.008--Not Available
Ventricular arrhythmia02.03.04.006--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Cardiotoxicity02.11.01.009; 12.03.01.007--Not Available
Gingival hyperpigmentation07.09.13.007--Not Available
Ejection fraction decreased13.14.02.003--
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Tumour necrosis24.04.02.013; 16.32.03.009--Not Available
Scrotal erythema23.03.06.013; 21.12.02.008--Not Available
Hepatic cancer metastatic09.04.02.006; 16.07.02.002--Not Available
Nail pigmentation23.02.05.007--Not Available
Angiopathy24.03.02.007--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages